Street Calls of the Week
TEL AVIV - SciSparc Ltd. (NASDAQ:SPRC) announced Wednesday it has entered into a definitive asset and share purchase agreement with Miza III Ventures Inc. (TSXV:MIZA.P), which will give SciSparc a controlling interest in the Canadian company. According to InvestingPro data, SciSparc maintains a strong liquidity position with a current ratio of 5.36 and holds more cash than debt on its balance sheet.
Under the agreement signed on October 9, SciSparc will transfer its clinical-stage pharmaceutical portfolio and its approximately 51% equity stake in SciSparc Nutraceuticals Inc. to Miza. These assets are valued at approximately $11.6 million, while Miza’s enterprise value is estimated at $3.3 million. The deal comes as SciSparc, currently valued at a market cap of $1.84 million, shows promising growth potential with analysts forecasting a 17.33% increase in revenue for the current year.
SciSparc will receive 63,300,000 common shares of Miza and up to 48,000,000 contingent rights based on pre-determined milestones. Following the transaction’s completion, SciSparc is expected to hold between 75% and 84% of Miza, which plans to rename itself NeuroThera Labs Inc.
The TSX Venture Exchange has conditionally approved the transaction, which is anticipated to close around October 22, 2025.
As part of the agreement, SciSparc intends to commit up to CAD1,000,000 (approximately $716,000) to Miza through an unsecured convertible note bearing 7% annual interest and maturing in two years.
SciSparc’s pharmaceutical assets being transferred include SCI-110 for Tourette syndrome (in phase IIb trials), SCI-110 for Alzheimer’s disease (completed phase II trials), and SCI-210 for autism, which began a randomized clinical trial in early 2024.
The information in this article is based on a company press release statement.
In other recent news, SciSparc Ltd. has announced several significant developments. The company has terminated its merger agreement with AutoMax Motors Ltd., including repayment terms for two outstanding loans provided to AutoMax. Additionally, SciSparc’s majority-owned subsidiary, MitoCareX Bio Ltd., will soon become a wholly owned subsidiary of N2OFF, Inc. after N2OFF shareholders approved the acquisition. The transaction involves N2OFF purchasing shares of MitoCareX for $700,000 and exchanging remaining shares for N2OFF common stock, representing 40% of N2OFF’s fully diluted capital stock.
Moreover, SciSparc has launched a quantum computing initiative aimed at advancing 3D protein modeling for drug discovery. This initiative is expected to enhance the accuracy of predicting protein structures and their interactions with ligands. These recent developments indicate a strategic shift for SciSparc, focusing on both biotechnology advancements and quantum computing technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.